⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488817 | 1.00 | — | — | |
| SCHEMBL488899 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL30595524 | 0.98 | SLC6A1 (0.64) | — | |
| Hydrochloric Acid SCHEMBL28195837 | 0.98 | SLC6A1 (0.64) | — | |
| SCHEMBL4940615 | 0.88 | SLC6A1 (0.52) | — | |
| SCHEMBL29499900 | 0.88 | SLC6A1 (0.52) | — | |
| SCHEMBL3207149 | 0.88 | SLC6A1 (0.52) | — | |
| Trifluoroacetic Acid SCHEMBL29878331 | 0.88 | SLC6A1 (0.58) | — | |
| SCHEMBL2917790 | 0.86 | SLC6A1 (0.48) | — | |
| SCHEMBL505815 | 0.86 | GABRA5 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270748-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| EP-1731520-A1 | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 | OSI Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| US-6686366-B1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | claimed |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | claimed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | claimed |
| EP-1246623-A4 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2003-05-14 | — | — | EP | claimed |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | claimed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | claimed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | claimed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| CN-1210517-A | Hydroxamic acid derivatives for use with treatment of diseases related to connective tissue degradation | UPJOHN CO (US) | 1999-03-10 | — | — | CN | claimed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4563579-A1 | MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-04 | — | — | EP | disclosed |
| US-20240270748-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-20020010216-A1 | New drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-01-24 | — | — | US | disclosed |
| WO-2001062236-A2 | NEW DRUG COMBINATIONS COMPRISING A NOREPINEPHRINE REUPTAKE INHIBITOR AND AN ANTIMUSCARINIC AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| CN-1210517-A | Hydroxamic acid derivatives for use with treatment of diseases related to connective tissue degradation | UPJOHN CO (US) | 1999-03-10 | — | — | CN | disclosed |